Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, talks on the role of STAT3 signaling in multiple myeloma, explaining that it is still necessary to determine the drivers of STAT signaling, as well as to better understand the impact of this signaling pathway on disease, and develop STAT3 inhibitors in order to determine the suitability of STAT3 as a therapeutic target in this disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.